Telehealth & Digital Health

Promising early safety data for a novel drug, KM-023, brings a potential first-ever targeted treatment for the devastating Olmsted syndrome a step closer.

A parent-led company gains a U.S. patent for a diazoxide formulation, offering new hope for managing behavioral symptoms in Prader-Willi syndrome.

With a fresh $28M investment, Verismo Therapeutics is set to unveil groundbreaking KIR-CAR data, aiming to revolutionize CAR T therapy for solid tumors.

A son's concern for his mother sparks an investment in a startup using AI to combat the hidden dangers of chronic dehydration affecting millions.

With its lead depression drug nearing Phase 3, AtaiBeckley faces investors to tackle the regulatory and commercial hurdles of psychedelic medicine.

Harrow partners with specialist LogiCare3PL for U.S. distribution, highlighting an industry shift towards agile, high-touch logistics for faster market access.

A new once-daily pill for hypoparathyroidism begins human testing, promising to replace burdensome injections and transform patient care. Is this the future?

With new funding, ImageneBio advances its unique OX40 inhibitor, IMG-007, for eczema and alopecia, but faces a divided Wall Street.

Nicklaus Children's Hospital now offers a sedation-free endoscopy, transforming a dreaded procedure into a quick, less stressful experience for young patients.

A new 'Intelligent Care Record' embeds AI to transform mental health care, raising the bar for competitors and sparking debate on ethical implementation.

As women in midlife turn to drugs like Ozempic, a new crisis is emerging: significant muscle loss. A new approach aims to protect metabolic health.

CHC: Creating Healthier Communities adds policy expert Edo Banach to its board, a strategic move to leverage his deep Medicare and Medicaid expertise.

A jury found Abbott's Similac caused a fatal gut disease in premature infants, igniting a legal firestorm over what the formula giant knew and when.

A hidden danger in IV lines causes thousands of preventable deaths. Now, one company is showcasing a new strategy to protect patients from this 'gross gap'.

A new partnership combines local infrastructure with global expertise, aiming to streamline development for startups and solidify Singapore's biotech leadership.

An exclusive partnership between Osmind and CareNet GPO gives small practices the power of large systems, aiming to broaden patient access to advanced mental healthcare.

A new non-invasive therapy using ultrasound to activate a cancer-targeting drug enters a crucial Phase 2b trial, offering new hope for glioblastoma patients.

Treating over 100,000 patients in two years, a novel gel therapy is leading a paradigm shift in interventional dry eye management. Here's how.

With its lead drug in Phase 3 and a strong Biogen partnership, Stoke Therapeutics prepares to update investors on its disease-modifying Dravet syndrome therapy.

A new clinical trial is underway for a next-gen aortic valve, promising a less invasive procedure and improved durability for millions of patients.